Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia

Blood

Volumn 120, Issue 20, 2012, Pages 4197-4204

  Yang, Jun J ^a   Cheng, Cheng ^a   Devidas, Meenakshi ^b   Cao, Xueyuan ^a   Campana, Dario ^a   Yang, Wenjian ^a   Fan, Yiping ^a   Neale, Geoff ^a   Cox, Nancy ^c   Scheet, Paul ^d   Borowitz, Michael J ^e   Winick, Naomi J ^f   Martin, Paul L ^g   Bowman, W Paul ^h   Camitta, Bruce ⁱ   Reaman, Gregory H ^j   Carroll, William L ^k   Willman, Cheryl L ^l   Hunger, Stephen P ^m   Evans, William E ^a   Pui, Ching Hon ^a   Loh, Mignon ⁿ   Relling, Mary V ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Duke University ^*  (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k NEW YORK UNIVERSITY   (United States)

^l UNIVERSITY OF NEW MEXICO   (United States)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; DEXAMETHASONE; METHOTREXATE;

ABCB1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PDE4B GENE; PRIORITY JOURNAL; PYGL GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 84869854208     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-440107     Document Type: Article

References (40)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
2. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):52-63.
3. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310-3322. (Pubitemid 30428458)
4. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14(12):2205-2222. (Pubitemid 32042262)
5. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4):1209-1217. (Pubitemid 29380401)
6. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):100-106.
7. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA. 2009;301(4):393-403.
8. Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009;114(7):1383-1386.
9. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105(12):4752-4758. (Pubitemid 40807300)
10. Davies SM, Borowitz MJ, Rosner GL, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(6):2984-2990.
11. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117(4):1049-1057. (Pubitemid 46556761)
12. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104(9):2690-2696. (Pubitemid 39434949)
13. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
14. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
15. Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics. 2006;22(1):7-12. (Pubitemid 43057002)
16. Korn JM, Kuruvilla FG, McCarroll SA, et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet. 2008;40(10):1253-1260.
17. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155(2):945-959. (Pubitemid 30397141)
18. Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet. 2007;80(6):1171-1178. (Pubitemid 47579352)
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
20. Cheng C, Pounds SB, Boyett JM, Pei D, Kuo ML, Roussel MF. Statistical significance threshold criteria for analysis of microarray gene expression data. Stat Appl Genet Mol Biol. 2004;3:Article36.
21. Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22(1):1-8.
22. French D, Yang W, Cheng C, et al. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood. 2009;113(19):4512-4520.
23. Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood. 2012;119(7):1658-1664.
24. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149-165. (Pubitemid 46758753)
25. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
26. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res. 2010;16(2):691-698.
27. Zaza G, Cheok M, Yang W, et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood. 2005;106(5):1778-1785. (Pubitemid 41208594)
28. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-542.
29. Heim S, Lage H. Transcriptome analysis of different multidrug-resistant gastric carcinoma cells. In Vivo. 2005;19(3):583-590. (Pubitemid 40568138)
30. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370(Pt 1):1-18. (Pubitemid 36259414)
31. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278(8):5493-5496. (Pubitemid 36800786)
32. Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMPassociated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005;105(1):308-316. (Pubitemid 40053098)
33. Meyers JA, Su DW, Lerner A. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol. 2009;182(9):5400-5411.
34. Kim SW, Rai D, Aguiar RC. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma. Clin Cancer Res. 2011;17(21):6723-6732.
35. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res. 2007;13(16):4920-4927. (Pubitemid 47294800)
36. Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood. 2002;99(9):3390-3397. (Pubitemid 34525321)
37. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003;20(11):1794-1803. (Pubitemid 37449453)
38. van Asperen J, van Tellingen O, Beijnen JH. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos. 2000;28(3):264-267. (Pubitemid 30137049)
39. Stanulla M, Schaffeler E, Arens S, et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hematol. 2005;81(1):39-44. (Pubitemid 40165422)
40. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72(5):314-321. (Pubitemid 38520728)